Evidence map›Paper›PMID 27791177›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2016

Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes.

Andrey S Dobroff, Sara D'Angelo, Bedrich L Eckhardt, Fortunato Ferrara, Daniela I Staquicini, Marina Cardó-Vila, Fernanda I Staquicini, Diana N Nunes, Kisu Kim, Wouter H P Driessen and 19 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 42 citations in OpenAlex.

  1. Stress-induced translocation of the endoplasmic reticulum chaperone GRP78/BiP and its impact on human disease and therapy.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Best of most possible worlds: Hybrid gene therapy vectors based on parvoviruses and heterologous viruses.Molecular therapy : the journal of the American Society of Gene Therapy · 2021
    Review
  8. Design and proof of concept for targeted phage-based COVID-19 vaccination strategies with a streamlined cold-free supply chain.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  9. Article
  10. Article
  11. Bacteriophages as Therapeutic and Diagnostic Vehicles in Cancer.Pharmaceuticals (Basel, Switzerland) · 2021
    Review
  12. Article
  13. Article
  14. Article
  15. Next-generation of targeted AAVP vectors for systemic transgene delivery against cancer.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 9 institutions in 5 countries.

Andrey S DobroffUniversity of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131.
Sara D'AngeloUniversity of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131.
Bedrich L EckhardtDepartment of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030.
Fortunato FerraraUniversity of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131.
Daniela I StaquiciniUniversity of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131.
Marina Cardó-VilaUniversity of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131.
Fernanda I StaquiciniUniversity of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131.
Diana N NunesInternational Research Center, A. C. Camargo Cancer Center, Sao Paulo 01508-010, Brazil.
Kisu KimMOGAM Biotechnology Institute, Yongin, Gyeonggi-do 16924, Korea.
Wouter H P DriessenDavid H. Koch Center, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030.
Amin HajitouHammersmith Hospital Campus, Imperial College London, London W12 0NN, United Kingdom.
Lesley C LomoUniversity of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131.
Marc BarryUniversity of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131.
Savitri KrishnamurthyDepartment of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030.
Aysegul SahinDepartment of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030.
Wendy A WoodwardDepartment of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030.
Eric R ProssnitzUniversity of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131.
Robin L AndersonDepartment of Oncology, Sir Peter MacCallum Cancer Centre, The University of Melbourne, Parkville, VIC 3010, Australia.ORCID http://orcid.org/0000-0002-6841-7422
Emmanuel Dias-NetoInternational Research Center, A. C. Camargo Cancer Center, Sao Paulo 01508-010, Brazil.
Ursa A Brown-GlabermanUniversity of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131.
Melanie E RoyceUniversity of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131.
Naoto T UenoDepartment of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030.
Massimo CristofanilliRobert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611.
Gabriel N HortobagyiDepartment of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030.
Serena MarchiòUniversity of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131.
Juri G GelovaniDepartment of Biomedical Engineering, Wayne State University, Detroit, MI 48201.
Richard L SidmanDepartment of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215 richard_sidman@hms.harvard.edu rpasqual@salud.unm.edu warap@salud.unm.edu.
Wadih ArapUniversity of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131; richard_sidman@hms.harvard.edu rpasqual@salud.unm.edu warap@salud.unm.edu.
Renata PasqualiniUniversity of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131; richard_sidman@hms.harvard.edu rpasqual@salud.unm.edu warap@salud.unm.edu.
University of New Mexico · USThe University of Texas MD Anderson Cancer Center · USAC Camargo Hospital · BRBeth Israel Deaconess Medical Center · USHammersmith Hospital · GBNorthwestern University · USThe University of Melbourne · AUUniversidade de São Paulo · BRWayne State University · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
WOMEN'S CANCERS RESEARCH PROGRAMP30CA118100 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Yolanda Sanchez · 2005 to 2026
$57.1M
Medical Research Council G0701159NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA118100
6 · The paper itself

Abstract

Inflammatory breast carcinoma (IBC) is one of the most lethal forms of human breast cancer, and effective treatment for IBC is an unmet clinical need in contemporary oncology. Tumor-targeted theranostic approaches are emerging in precision medicine, but only a few specific biomarkers are available. Here we report up-regulation of the 78-kDa glucose-regulated protein (GRP78) in two independent discovery and validation sets of specimens derived from IBC patients, suggesting translational promise for clinical applications. We show that a GRP78-binding motif displayed on either bacteriophage or adeno-associated virus/phage (AAVP) particles or loop-grafted onto a human antibody fragment specifically targets orthotopic IBC and other aggressive breast cancer models in vivo. To evaluate the theranostic value, we used GRP78-targeting AAVP particles to deliver the human

Indexed as

AAVPgene therapyinflammatory breast cancerligand-directed theranosticsmolecular imaging

Identifiers

PMID27791177
PMCPMC5111698
OpenAlexW2537158491

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.